Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

20163,568 citationsJournal Articlebronze Open Access

Authors

Christoph Wanner · University of Würzburg

Silvio E. Inzucchi · Yale University

John M. Lachin · George Washington University

David Fitchett · University of Toronto

Maximilian von Eynatten · Boehringer Ingelheim (Taiwan)

Michaela Mattheus · Boehringer Ingelheim (Taiwan)

Odd Erik Johansen

Abstract

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. (Funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Chronic Kidney Disease and Diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 4, pp. 323-334

DOI: 10.1056/nejmoa1515920

Field-Weighted Citation Impact: 320.10